- Home
- ACXP vs LPCN Comparison
ACXP vs LPCN Comparison
Compare ACXP & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACXP
- LPCN
- Stock Information
- Founded
- ACXP 2017
- LPCN 1997
- Country
- ACXP United States
- LPCN United States
- Employees
- ACXP N/A
- LPCN N/A
- Industry
- ACXP Biotechnology: Pharmaceutical Preparations
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- ACXP Health Care
- LPCN Health Care
- Exchange
- ACXP Nasdaq
- LPCN Nasdaq
- Market Cap
- ACXP 31.4M
- LPCN 27.1M
- IPO Year
- ACXP 2021
- LPCN N/A
- Fundamental
- Price
- ACXP $0.88
- LPCN $4.37
- Analyst Decision
- ACXP Strong Buy
- LPCN Strong Buy
- Analyst Count
- ACXP 1
- LPCN 1
- Target Price
- ACXP $12.00
- LPCN $10.00
- AVG Volume (30 Days)
- ACXP 455.1K
- LPCN 34.0K
- Earning Date
- ACXP 03-14-2025
- LPCN 03-06-2025
- Dividend Yield
- ACXP N/A
- LPCN N/A
- EPS Growth
- ACXP N/A
- LPCN N/A
- EPS
- ACXP N/A
- LPCN N/A
- Revenue
- ACXP N/A
- LPCN $7,922,926.00
- Revenue This Year
- ACXP N/A
- LPCN N/A
- Revenue Next Year
- ACXP N/A
- LPCN N/A
- P/E Ratio
- ACXP N/A
- LPCN N/A
- Revenue Growth
- ACXP N/A
- LPCN N/A
- 52 Week Low
- ACXP $0.68
- LPCN $3.20
- 52 Week High
- ACXP $4.15
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- ACXP 49.25
- LPCN 38.51
- Support Level
- ACXP $0.68
- LPCN $4.48
- Resistance Level
- ACXP $1.25
- LPCN $4.89
- Average True Range (ATR)
- ACXP 0.10
- LPCN 0.35
- MACD
- ACXP 0.02
- LPCN -0.06
- Stochastic Oscillator
- ACXP 35.61
- LPCN 9.60
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.